Role of Small Breast Epithelial Mucin (SBEM) in Breast Cancer
*Liang Liu Department Of Oncology, Hospital Of Guiyang Medical University,, China
*Corresponding Author: Liang Liu
Department Of Oncology, Hospital Of Guiyang Medical University,, China Email:firstname.lastname@example.org
Published on: 2014-11-01
SBEM as a kind of secreted protein, which expressed only in mammary gland and salivary gland, can be used to be a tumor marker in breast cancer and specific target in treatment. SBEM detection in Peripheral blood (PB) and tissue of breast cancer patients maybe helpful for early diagnosis, choice of treatment, decision of the degree of malignancy and risk prediction of recurrence. The changing of expression level can predict the curative effect of neoadjuvant chemotherapy. SBEM-mRNA had sensitivity and accuracy in bone marrow micrometastases in breast cancer and had direct correlation with TNM stage. SBEM is an independent risk predictor and may offer utility as a prognostic marker in triple-negative breast cancer patients. The detection of SBEM will have better application prospect because of its clear advantage in detecting of micrometastasis in breast cancer and clinical supervision.
SBEM; Breast cancer; Marker
Breast cancer is the most common malignancy and is second only to lung cancer in mortality among women worldwide. Breast cancer remains to be an important public health problem. The 5-year survival rate is approximately 75% for women with locally advanced breast cancer. However, if the cancer has metastasized, the average survival time falls to <2 years. It is clear that metastatic spreading occurs in about 50% of cases with localized breast cancer, and that up to 30% of patients with lymph nodes negative disease will develop distant metastases within 5 years. Therefore, it is probably the establishment of micro-metastases that due to recurrence. Detection of breast cancer micrometastases based on specific genetic markers may provide useful information to guide early therapeutic methods.